Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.
PURPOSE: This study aimed to carry out a comprehensive analysis of genetic and epigenetic changes of the von Hippel Lindau (VHL) gene in patients with conventional (clear cell) renal cell carcinoma and to determine their significance relative to clinicopathologic characteristics and outcome. EXPERIMENTAL DESIGN: The VHL status in 86 conventional renal cell carcinomas was determined by mutation detection, loss of heterozygosity (LOH), and promoter methylation analysis, extending our original cohort to a total of 177 patients. Data were analyzed to investigate potential relationships between VHL changes, clinical parameters, and outcome. RESULTS: LOH was found in 89.2%, mutation in 74.6%, and methylation in 31.3% of evaluable tumors; evidence of biallelic inactivation (LOH and mutation or methylation alone) was found in 86.0% whereas no involvement of VHL was found in only 3.4% of samples. Several associations were suggested, including those between LOH and grade, nodal status and necrosis, mutation and sex, and methylation and grade. Biallelic inactivation may be associated with better overall survival compared with patients with no VHL involvement, although small sample numbers in the latter group severely limit this analysis, which requires independent confirmation. CONCLUSIONS: This study reports one of the highest proportions of conventional renal cell carcinoma with VHL changes, and suggests possible relationships between VHL status and clinical variables. The data suggest that VHL defects may define conventional renal cell carcinomas but the clinical significance of specific VHL alterations will only be clarified by the determination of their biological effect at the protein level rather than through genetic or epigenetic analysis alone. (Clin Cancer Res 2009;15(24):7582-92).
Young
Alison C
AC
Authors' Affiliations: Cancer Research UK Clinical Centre, Cancer Research UK Mutation Detection Facility, and Pyrah Department of Urology, St James's University Hospital, and Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom; and Cancer Research UK Renal Molecular Oncology Group, University of Birmingham, Edgbaston, United Kingdom.
Craven
Rachel A
RA
Cohen
Dena
D
Taylor
Claire
C
Booth
Christopher
C
Harnden
Patricia
P
Cairns
David A
DA
Astuti
Dewi
D
Gregory
Walter
W
Maher
Eamonn R
ER
Knowles
Margaret A
MA
Joyce
Adrian
A
Selby
Peter J
PJ
Banks
Rosamonde E
RE